Effectiveness of Phenolic Antioxidants in Experimental Model of Benign Prostatic Hyperplasia


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

Experimental model of sulpiride-provoked benign prostatic hyperplasia was employed to comparatively assess the effect of phenolic antioxidants (dihydroquercetin, p-thyrozol, dibornol, and prostagenin) on prostate morphology. All examined agents decreased the degree of hyperplasia in acinar epithelium; the greatest efficacy was demonstrated by prostagenin. Moreover, dihydroquercetin and p-thyrozol increased the cross-section area of acinar lumina and prostate volume, which is inadmissible in this pathology. These results suggest that the use of phenolic antioxidants in the therapy of benign prostatic hyperplasia should be strictly controlled.

About the authors

T. G. Borovskaya

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Author for correspondence.
Email: repropharm@yandex.ru
Russian Federation, Tomsk

S. I. Kamalova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

V. A. Grigor’eva

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

M. E. Poluektova

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

A. V. Vychuzhanina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

A. V. Kuchin

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Russian Federation, Syktyvkar

I. Yu. Chukicheva

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Russian Federation, Syktyvkar

E. V. Buravlev

Institute of Chemistry, Komi Scientific Center, Ural Division of Russian Academy of Sciences

Email: repropharm@yandex.ru
Russian Federation, Syktyvkar

T. I. Fomina

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

M. B. Plotnikov

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

V. E. Goldberg

Research Institute of Oncology, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk

A. M. Dygai

E. D. Goldberg Research Institute of Pharmacology and Regenerative Medicine, Tomsk National Research Medical Center

Email: repropharm@yandex.ru
Russian Federation, Tomsk


Copyright (c) 2019 Springer Science+Business Media, LLC, part of Springer Nature

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies